Company Overview

bioAffinity Technologies, Inc. is a U.S.-based biotechnology and diagnostics company focused on the development of noninvasive diagnostic tests and targeted therapeutics, primarily for lung disease and cancer detection. The company operates in the healthcare and life sciences sectors, with activities spanning diagnostics, laboratory services, and cancer therapeutics research. Its primary commercial focus has been the development and commercialization of CyPath® Lung, a flow cytometry-based diagnostic test designed to aid in the detection of lung cancer in high-risk patients. The company also conducts laboratory operations through Precision Pathology Laboratory Services, which provides pathology and clinical laboratory testing services.

The company’s revenue drivers include diagnostic testing services, laboratory operations, and the potential future commercialization of proprietary diagnostic technologies and therapeutics. bioAffinity Technologies positions itself around noninvasive diagnostics that aim to improve early detection rates while reducing unnecessary invasive procedures. The company was founded in 2014 and later became publicly traded on Nasdaq under the ticker BIAF. Its evolution has included expansion from research-stage biomarker development into commercial laboratory operations and clinical deployment initiatives tied to pulmonary disease diagnostics.

Business Operations

bioAffinity Technologies conducts operations through diagnostic development activities and laboratory service operations. Its principal operating assets include CyPath® Lung, proprietary biomarker and flow cytometry technologies, and the company’s CLIA-certified laboratory operations under Precision Pathology Laboratory Services. The company generates revenue primarily through pathology and laboratory testing services while continuing development and commercialization efforts tied to lung cancer diagnostics. Public filings indicate that the company’s operational model combines laboratory services with proprietary diagnostic product development intended to support recurring clinical utilization.

The company’s activities are concentrated primarily within the United States, though its technologies may have broader applicability in international healthcare markets. bioAffinity Technologies has collaborated with academic researchers, clinical investigators, and healthcare institutions in support of validation studies and product development. The company also maintains intellectual property related to cancer diagnostics and therapeutic discovery programs, including work involving macrophage-targeting technologies and research into targeted cancer treatments. Data regarding material international joint ventures or large-scale overseas subsidiaries remains limited based on available public disclosures.

Strategic Position & Investments

bioAffinity Technologies’ strategic direction centers on expanding adoption of CyPath® Lung, growing laboratory service revenues through Precision Pathology Laboratory Services, and advancing oncology-focused research programs. Company disclosures and investor communications indicate that management views early cancer detection and noninvasive diagnostics as significant market opportunities, particularly in lung cancer screening populations. The company has also emphasized integration between proprietary diagnostics and laboratory infrastructure as part of its commercialization strategy.

The acquisition of Precision Pathology Laboratory Services represented a significant operational investment, providing internal laboratory capabilities and an established pathology services platform. In addition to diagnostics, the company has pursued development initiatives involving targeted cancer therapeutics and immune-related technologies. Publicly available information also references research involving extracellular vesicles, macrophage biology, and tumor microenvironment applications. While management has communicated ambitions for broader commercialization and pipeline expansion, some future-stage initiatives remain in development and are subject to regulatory, clinical, and financing considerations.

Geographic Footprint

bioAffinity Technologies is headquartered in San Antonio, Texas, and its primary operational footprint is concentrated within the United States. The company’s laboratory and diagnostic activities are primarily tied to U.S. clinical markets, including pulmonology, pathology, and cancer screening networks. Its laboratory operations support healthcare providers and testing services domestically, with commercial emphasis on regions where lung cancer screening programs are expanding.

Although the company does not currently maintain a widely disclosed multinational operating structure comparable to larger diagnostics firms, its technologies target healthcare challenges with global relevance. Public disclosures suggest interest in broader commercialization opportunities beyond domestic markets, but verified large-scale international operational infrastructure or substantial foreign revenue exposure remains limited in available public records.

Leadership & Governance

bioAffinity Technologies was founded under the leadership of Maria Zannes, who has played a central role in the company’s strategic development, financing, and commercialization initiatives. The company’s leadership has emphasized innovation in early-stage cancer detection, integration of laboratory services, and development of clinically actionable diagnostic technologies. Governance and operational strategy have focused on expanding commercial capabilities while advancing proprietary research programs.

Key executives and leadership personnel include:

• Maria Zannes – President and Chief Executive Officer
• Michael Wilson – Chief Financial Officer
• Maximilian Diehn, M.D., Ph.D. – Scientific and clinical advisory leadership contributor associated with lung cancer research initiatives
• Fred Frankel – Laboratory and pathology operations leadership associated with Precision Pathology Laboratory Services

Public company governance disclosures indicate that management prioritizes clinical validation, commercialization discipline, and expansion of diagnostic applications tied to oncology and pulmonary disease detection. Certain executive and advisory roles have evolved over time, and some leadership information may vary across filings and corporate announcements.